GSK ups Theravance stake to 27% with $213mn share purchase
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline invested in its collaborator Theravance for at least the third time on 2 April, with a $212.9 million purchase of the South San Francisco-based biotech company's stock increasing GSK's stake from 18.3% to 26.8%.